Michigan University has backed a $4m series A round for ViewPoint, which is developing therapies for eye diseases.
ViewPoint Therapeutics, a US-based biotechnology company to treat eye diseases, has raised $4m in its series A round from a consortium including Michigan University through its Michigan Investment in New Technology Startups (Mints) initiative.
Venture capital firms Mission Bay Capital and Lagunita BioSciences co-led the A round, which also included the Biotechnology Value Fund, Asset Management Ventures and angel investors.
ViewPoint was founded in 2014 based on technology developed in the lab of Jason Gestwicki at Michigan University in collaboration with the lab of Usha Andley at Washington University in St. Louis.
Founded in 2011, Mints is a $25m venture fund for the University of Michigan to leverage commercialisation efforts by the Office of Technology Transfer that in February joined the €6.7m round for Belgium-based Confo Therapeutics.
